Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.

Tanner E RothsteinScott A CunninghamRachelle A RiekeJill M MainellaMelissa M MutchlerRobin Patel

Published in: Antimicrobial agents and chemotherapy (2022)

The epidemiology of macrolide resistance in Mycoplasma ( Mycoplasmoides ) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.

Keyphrases

respiratory tract
primary care
gene expression
electronic health record
copy number
big data
dna methylation
genome wide analysis